semaglutide ban update Fifth Circuit probes FDA on compounded GLP-1s Compounded Semaglutide & Tirzepatide 2025:

Wilson TWH, Zeneng W, Yiying F, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen S

Evidence from studies of brand-name GLP-1 medications suggests that weight regain is common after discontinuation, particularly without sustained lifestyle modifications

Stay tuned, kidney blog incoming next week (I promise) (As long as theres no other late breaking GLP-1 news) References:

If you require stimulant therapy for a diagnosed condition, your prescribing physician should monitor your cardiovascular status more frequently during semaglutide treatment

The segment also gained from refill-driven repeat purchases and pharmacist-led nutritional guidance targeting side-effect management and companion wellness support for GLP-1 therapy consumers

By lowering the systemic oxidative burden, NAC helps "rescue" these exhausted immune cells